NASDAQ: IRONDisc Medicine Inc Stock
$49.42+2.27 (+4.81%)
Updated Apr 30, 2025
IRON Price
$49.42
Fair Value Price
N/A
Market Cap
$1.71B
52 Week Low
$28.25
52 Week High
$68.73
P/E
-12.48x
P/B
3.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$109.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$94M
Beta
0.82
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IRON Overview
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRON's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IRON
Ranked#228 of 462
Ranked#228 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important IRON news, forecast changes, insider trades & much more!
IRON News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IRON is good value based on its book value relative to its share price (3.85x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
IRON is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IRON due diligence checks available for Premium users.
Valuation
IRON fair value
Fair Value of IRON stock based on Discounted Cash Flow (DCF)
Price
$49.42
Fair Value
$16.05
Overvalued by
207.82%
IRON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.48x
Industry
-162.28x
Market
29.18x
IRON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.85x
Industry
4.45x
IRON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IRON's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.5M
Profit Margin
0%
IRON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$496.8M
Liabilities
$53.2M
Debt to equity
0.12
IRON's short-term assets ($493.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRON's short-term assets ($493.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.6M
Investing
-$1.4M
Financing
$28.8M
IRON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IRON vs Biotech Stocks
Disc Medicine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.